Literature DB >> 3061999

The in-vitro degradation at 37 degrees C of vancomycin in serum, CAPD fluid and phosphate-buffered saline.

L O White1, R Edwards, H A Holt, A M Lovering, R G Finch, D S Reeves.   

Abstract

Solutions of vancomycin in phosphate-buffered saline, peritoneal dialysis effluent fluid and human serum were incubated at 37 degrees C for ten days and sampled at daily intervals. The samples were assayed for vancomycin content by a microbiological assay, HPLC and polarisation fluoroimmunoassay (Abbott TDX). The results obtained by HPLC and microbiological assay agreed well and indicated approximately 50% loss over ten days in serum and buffered saline and over 70% loss in dialysate. TDX results indicated losses of only 20% and 40%, respectively. Degradation products were prepared from vancomycin by acid hydrolysis and purified by HPLC. These purified products were shown to cross-react in the TDX assay. It is suggested that the TDX assay becomes non-specific in the presence of vancomycin breakdown products and thus overestimates true vancomycin concentrations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3061999     DOI: 10.1093/jac/22.5.739

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

Review 1.  Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Authors:  K A Rodvold; J A Everett; R D Pryka; D M Kraus
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Dosage recommendation of vancomycin during haemodialysis with highly permeable membranes.

Authors:  J Zoer; A M Schrander-van der Meer; W T van Dorp
Journal:  Pharm World Sci       Date:  1997-08

3.  Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.

Authors:  Omar Vesga; Maria Agudelo; Beatriz E Salazar; Carlos A Rodriguez; Andres F Zuluaga
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 4.  The therapeutic monitoring of antimicrobial agents.

Authors:  E J Begg; M L Barclay; C J Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

5.  Vancomycin pharmacokinetics in burn patients and intravenous drug abusers.

Authors:  M J Rybak; L M Albrecht; J R Berman; L H Warbasse; C K Svensson
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

6.  Studies on the metabolism and degradation of vancomycin in simulated in vitro and aquatic environment by UHPLC-Triple-TOF-MS/MS.

Authors:  Mengsi Cao; Yanru Feng; Yan Zhang; Weijun Kang; Kaoqi Lian; Lianfeng Ai
Journal:  Sci Rep       Date:  2018-10-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.